Adaptive Biotechnologies Corporation
ADPT
$17.50
$0.724.29%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 70.87M | 71.68M | 93.97M | 58.88M | 52.44M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 70.87M | 71.68M | 93.97M | 58.88M | 52.44M |
| Cost of Revenue | 42.33M | 39.99M | 41.83M | 42.13M | 41.18M |
| Gross Profit | 28.54M | 31.69M | 52.15M | 16.75M | 11.26M |
| SG&A Expenses | 47.33M | 44.04M | 41.43M | 41.36M | 40.45M |
| Depreciation & Amortization | 419.00K | 429.00K | 428.00K | 423.00K | 419.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 90.08M | 84.45M | 83.68M | 83.92M | 82.05M |
| Operating Income | -19.21M | -12.77M | 10.29M | -25.04M | -29.60M |
| Income Before Tax | -20.02M | -13.58M | 9.55M | -25.59M | -29.83M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -20.02M | -13.58M | 9.55M | -25.59M | -29.83M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -18.00K | 0.00 | 1.00K | -21.00K | -22.00K |
| Net Income | -20.03M | -13.58M | 9.55M | -25.61M | -29.85M |
| EBIT | -19.21M | -12.77M | 10.29M | -25.04M | -29.60M |
| EBITDA | -15.37M | -8.58M | 14.70M | -20.53M | -24.87M |
| EPS Basic | -0.13 | -0.09 | 0.06 | -0.17 | -0.20 |
| Normalized Basic EPS | -0.08 | -0.06 | 0.04 | -0.11 | -0.13 |
| EPS Diluted | -0.13 | -0.09 | 0.06 | -0.17 | -0.20 |
| Normalized Diluted EPS | -0.08 | -0.06 | 0.04 | -0.11 | -0.13 |
| Average Basic Shares Outstanding | 155.52M | 153.13M | 152.43M | 152.08M | 149.20M |
| Average Diluted Shares Outstanding | 155.52M | 153.13M | 163.16M | 152.08M | 149.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |